Every material Form 8-K Parker Hannifin filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Parker-Hannifin Corporation reported record sales of $6.0 billion and increased net income for the fiscal first quarter ended September 30, 2026, alongside the completion of the Filtration Group acquisition. Driven by double-digit organic growth and record order rates pushing backlog to $13.7 billion, management raised full-year fiscal 2027 guidance for sales growth, adjusted margins, EPS, and free cash flow. This performance demonstrates strong demand across all market verticals and positive integration progress for shareholders.
Sales for the quarter ended September 30, 2026, increased 18% to a record $6.0 billion, with organic sales up 11.5%.
Diluted earnings per share reached $6.92, while adjusted EPS rose 23% to a record $8.90.
Order rates increased 13% on a rolling 12-month basis, bringing total backlog to a record $13.7 billion.
Full-year fiscal 2027 guidance was raised for organic sales growth, adjusted segment operating margin, adjusted EPS, and free cash flow.
Parker-Hannifin completed its acquisition of Filtration Group on August 13, 2026, for a cash purchase price of $9.25 billion, subject to a net working capital adjustment. The company borrowed $5.25 billion under a 364-Day delayed draw term loan and $2.50 billion under a Three-Year delayed draw term loan to help pay the purchase price and related fees and expenses.
Cash purchase price of $9.25 billion on a cash-free, debt-free basis, subject to a net working capital adjustment
Merger completed August 13, 2026, under the Merger Agreement signed November 10, 2025
Borrowed $5.25 billion under the 364-Day Credit Facility and $2.50 billion under the Three-Year Credit Facility on August 13, 2026
Credit agreements dated December 10, 2025, with Barclays Bank PLC and KeyBank National Association as administrative agents
Parker Hannifin reported fourth-quarter fiscal 2026 sales of $5.8 billion, up 9.8%, and diluted EPS of $8.54, up 19% from $7.15 a year earlier. The company guided fiscal 2027 EPS to $30.00 to $31.00, excluding pending acquisitions, and raised its adjusted segment operating margin target to 30% by fiscal 2031.
Q4 net income was $1.1 billion, up 18%; adjusted EPS was $9.27, up 21%, which includes an $84 million tariff refund benefit to cost of sales.
Fiscal 2027 guidance: reported sales growth of 5.5% to 8.5% and EPS of $30.00 to $31.00, or $34.25 to $35.25 adjusted.
Adjusted segment operating margin target raised by 300 basis points to 30% by fiscal 2031.
Fiscal 2026 cash flow from operations was $4.4 billion, and the company returned nearly $2 billion to shareholders.
Parker Hannifin reported record fiscal third-quarter sales of $5.5 billion, up 11%, and adjusted EPS of $8.17, up 18%. The company raised its fiscal 2026 outlook, now expecting adjusted EPS of $31.20, and GAAP net income and diluted EPS declined year over year because the prior-year period included a one-time $180 million tax benefit.
Q3 sales rose 11% to a record $5.5 billion, with organic sales up 6.5%.
Diluted EPS was $7.06, down from $7.37 a year earlier, which included a one-time $1.37 discrete tax benefit; adjusted EPS rose 18% to a record $8.17.
Fiscal 2026 guidance: EPS of $27.10 ($31.20 adjusted) and reported sales growth of 7%.
Backlog reached a record $12.5 billion, and the company repurchased $275 million of shares in the quarter.
Parker-Hannifin director Kevin A. Lobo told the company on March 13, 2026, that he will not stand for reelection to the board at the 2026 Annual Meeting of Shareholders. He cited his election to the board of GE HealthCare Technologies Inc. and said the decision was not due to any disagreement with the company over operations, policies or practices. He will remain a director until his current term expires.
Kevin A. Lobo notified the company on March 13, 2026 that he will not stand for reelection
Lobo has served as a Director since 2013
Reason given: election to the board of GE HealthCare Technologies Inc.
Filing states no disagreement with the company on operations, policies or practices
Parker-Hannifin reported fiscal second-quarter results for the quarter ended December 31, 2025, with net sales up 9% to a record $5.2 billion and adjusted EPS up 17% to $7.65. Reported net income fell 11% to $845 million and diluted EPS fell 9% to $6.60, because the year-earlier quarter included a one-time after-tax divestiture gain. The company raised its fiscal 2026 guidance and said it has a definitive agreement to acquire Filtration Group Corporation.
Net sales rose 9% to $5.2 billion, with organic sales up 6.6%
Diluted EPS was $6.60, down from $7.25; adjusted EPS rose 17% to $7.65
Fiscal 2026 EPS guidance raised to $26.26 to $26.86, or $30.40 to $31.00 adjusted
Definitive agreement to acquire Filtration Group Corporation announced; the filing does not state a price
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Parker Hannifin filing is on SEC EDGAR ↗. 8-K briefs of other companies →